【药物名称】
化学结构式(Chemical Structure):
参考文献No.45249
标题:Pyrrolidine modulators of chemokine receptor activity
作者:Mills, S.G.; Kim, D.; Hale, J.; MacCoss, M.; Berk, S.; Chapman, K.; Lynch, C.; Caldwell, C.; Willoughby, C.; Kim, R.M. (Merck & Co., Inc.)
来源:US 6498161; WO 0059498
合成路线图解说明:

3-Fluorocinnamic acid (I) is activated as the mixed anhydride (II) with pivaloyl chloride and subsequently coupled to the lithium anion of (S)-4-benzyloxazolidin-2-one (III) to provide the N-acyl oxazolidinone (IV). Cycloaddition of the cinnamoyl derivative (IV) with N-methoxymethyl-N-trimethylsilylmethyl benzylamine (V) in the presence of trifluoroacetic acid gives rise to a diastereomeric mixture of trans-pyrrolidines (VI) and (VII), separable by column chromatography. The desired isomer (VII) is then reduced by LiAlH4 to alcohol (VIII), which is further protected as the silyl ether (IX). Debenzylation of (IX) by transfer hydrogenolysis with ammonium formate and Pearlman's catalyst furnishes pyrrolidine (X).

合成路线图解说明:

Condensation of oxalyl chloride (XI) with N,O-dimethylhydroxylamine produces N,N'-dimethyl-N,N'-dimethoxy oxamide (XII). This is then condensed with cyclobutylmethylmagnesium bromide (XIII) to afford the ketoamide (XIV). Asymmetric keto group reduction employing (R)-alpine borane leads to the (S)-alcohol (XV) in 91% enantiomeric excess. Hydrolysis of the N-methoxyamide function of (XV) to provide hydroxyacid (XVI) is then accomplished employing potassium tert-butoxide in the presence of the equimolecular amount of H2O in THF. Alkylation of hydroxyacid (XVI) with benzyl bromide and Et3N furnishes the corresponding benzyl ester (XVII). Treatment of (XVII) with trifluoromethanesulfonic anhydride gives rise to triflate (XVIII), which is further condensed with pyrrolidine (X) to produce (XIX). After desilylation of (XIX) with tetrabutylammonium fluoride, the resultant alcohol (XX) is oxidized to aldehyde (XXI) under Swern conditions.

合成路线图解说明:

Reductive amination of N-Boc-4-piperidone (XXII) with benzylamine, followed by benzyl group hydrogenolysis of the resultant secondary amine (XXIII) gives rise to N-Boc-4-aminopiperidine (XXIV). This is then condensed with 2-chloro-5-trifluoromethylpyrimidine (XXV) to furnish adduct (XXVI). Subsequent alkylation of amine (XXVI) with allyl bromide in the presence of sodium hexamethyldisilazide affords the N-allyl amine (XXVII), which is further hydrogenated to the N-propyl analogue (XXVIII). Acidic hydrolysis of (XXVIII) then removes the N-Boc protecting group, providing piperidine (XXIX). (1,2)

合成路线图解说明:

Catalytic hydrogenolysis of the benzyl ester (XXI) affords the carboxylic acid (XXX). The aldehyde-acid (XXX) is then reductively aminated with piperidine (XXIX) in the presence of NaBH(OAc)3 to produce the title compound. (1,2)

参考文献No.718600
标题:1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains
作者:Willoughby, C.A.; Rosauer, K.G.; Hale, J.J.; Budhu, R.J.; Mills, S.G.; Chapman, K.T.; MacCoss, M.; Malkovitz, L.; Springer, M.S.; Gould, S.L.; DeMartino, J.A.; Siciliano, S.J.; Cascieri, M.A.; Carella, A.; Carver, G.; Holmes, K.; Schleif, W.A.; et al.
来源:Bioorg Med Chem Lett 2003,13(3),427
合成路线图解说明:

Reductive amination of N-Boc-4-piperidone (XXII) with benzylamine, followed by benzyl group hydrogenolysis of the resultant secondary amine (XXIII) gives rise to N-Boc-4-aminopiperidine (XXIV). This is then condensed with 2-chloro-5-trifluoromethylpyrimidine (XXV) to furnish adduct (XXVI). Subsequent alkylation of amine (XXVI) with allyl bromide in the presence of sodium hexamethyldisilazide affords the N-allyl amine (XXVII), which is further hydrogenated to the N-propyl analogue (XXVIII). Acidic hydrolysis of (XXVIII) then removes the N-Boc protecting group, providing piperidine (XXIX). (1,2)

合成路线图解说明:

Catalytic hydrogenolysis of the benzyl ester (XXI) affords the carboxylic acid (XXX). The aldehyde-acid (XXX) is then reductively aminated with piperidine (XXIX) in the presence of NaBH(OAc)3 to produce the title compound. (1,2)

Drug Information Express,Drug R&D,Chemical Database,Patent Search.
Copyright © 2006-2024 Drug Future. All rights reserved.Contact Us